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                                 INTRODUCTION 
  Systemic Lupus Erythematosus (SLE) is an autoimmune disease in 
which organs and cells undergo damage mediated by tissue-binding auto 
antibodies and immune complexes.
1 
INCIDENCE AND PREVALENCE 
 The overall prevalence of  SLE varies from 12 to 50.8 cases per 1 lakh 
persons.
4
 
  Three British groups who used several sources to ascertain cases arrived 
at prevalence rates ranging from 24.7 to 26.1 per 1 lakh persons
5
. 
 The average annual incidence of SLE in united states vary from 2.0 to 7.6 
cases per 1 lakh  persons per year.
4  
Prevalence of SLE in the united states is 15 
– 50 per 1 lakh persons.1 
  In a study conducted near Delhi, the prevalence of SLE was found to be 
3.2 per 1 lakh population.
3
 
AGE AND SEX DISTRIBUTION 
  Ninety percent of patients are women of child-bearing age. people of 
both sexes, all ages,  and all ethnic groups are susceptible.
1 
             Female to male ratio is 9:1 between menarche and menopause, 3:1 in 
young and old .
2
 
  Age specific incidence rates in black and Caucasian females were 
greatest in 15 – 44 year age group.4 
PATHOGENESIS AND ETIOLOGY 
  SLE is a multigenic disease
1
.  Interactions between susceptibility genes 
and environmental factors result in abnormal immune responses. Those 
responses include 
1. Activation of innate immunity .  
2. Lowered activation thresholds of adaptive immunity cells . 
3. Ineffective regulatory and inhibitory CD4+ and CD8+ T cells. 
4. Reduced clearance of  apoptotic cells and of immune complexes.1 
       Self antigens are available for recognition by the immune system in the 
surface blebs of apoptotic cells; thus antigens, antibodies and immune 
complexes persists for prolonged period of time , allowing inflammation and 
disease to develop.
1
 
  
  
CLINICAL MANIFESTATIONS OF SLE AND                                 
PREVALENCE.1 
             Manifestation   Prevalence(%) 
Musculoskeletal 95% 
Cutaneous 80% 
Hematologic 85% 
Neurologic 60% 
Cardiopulmonary 60% 
Renal 30-50 % 
Gastrointestinal 40% 
Thrombosis 15% 
Ocular 15% 
 
 
 
 
AUTOANTIBODIES IN SLE.
1 
 
Antinuclear antibodies: 
 
Anti-dsDNA
 
 
Anti-sm
 
 Anti-RNP  
 Anti-Ro 
  Anti-La 
  Antihistone  
 Antiphospholipid  
 Antierythrocyte 
  Antiplatelet   
  Antineuronal  
 Antiribosomal P 
 
1997 UPDATE OF THE 1982 AMERICAN COLLEGE OF 
RHEUMATOLOGY CLASSIFICATION CRITERIA FOR SLE.
6
  
1. Malar rash 
 Fixed erythema, flat or raised, over the malar eminences. 
 
2. Discoid rash 
 Erythematous circular raised patches with adherent keratotic scaling  and 
follicular plugging; atrophic scarring may occur.
 
3. Photosensitivity 
 Skin rash as a result of unusual reaction to sun light, by patient history or 
physician observation.
 
4. Oral ulcers 
         Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician. 
5. Arthritis 
        Non erosive arthritis involving two or more peripheral joints, characterized 
by tenderness swelling or effusion. 
6. Serositis  
 Pleuritis: convincing history of pleuritic pain or rub or evidence of 
pleural effusion. 
or 
 Pericarditis: documented by ECG or rub or evidence of pericardial 
effusion. 
7. Renal Disorder  
 Persistant proteinuria > 0.5 g / day or more than or equal to 3+ if 
quantitation not performed. 
or 
 Cellular casts: may be red cell, haemoglobin, granular, tubular, or mixed. 
 8. Neurologic disorder 
      Seizures or Psychosis: in the absence of offending drugs or known 
metabolic derangement. 
 9. Hematologic Disorder  
      Haemolytic anaemia: with reticulocytosis   or 
      Leukopenia : less than 4000/ mm 
3
   or 
      Lymphopenia less than 1500/mm 
3  
or 
      Thrombocytopenia less than 100,000/mm 
3 
in the absence of offending 
drug. 
10. Immunologic disorder 
     Anti – DNA: Antibody to native DNA in abnormal titer.  
         or 
    Anti – sm: presence of antibody to sm nuclear antigen. 
     or 
 Positive finding of antiphospholipid antibodies. 
11. Positive antinuclear antibody. 
 An abnormal titer of ANA by immunofluorescence or an equivalent assay 
at any point in time and in the absence of drugs known to be associated with 
drug induced lupus syndrome. 
 
If more than or equal to 4 of these criteria, well documented, are present 
at any time in a patient’s history the diagnosis is likely to be SLE. Specificity is 
95%; sensitivity is 75%.
1 
                                           
 
  
                                  AIMS OF THE STUDY 
 
1. To find out the prevalence of cardiac manifestations in patients 
with Systemic Lupus  Erythematosus. 
 
2. To find out the commonest and least common cardiac 
manifestation in Systemic Lupus Erythematosus. 
 
3. To find out the various types of cardiac manifestations in 
Systemic Lupus Erythematosus. 
 
4. To compare the results of this study with the results of other 
studies in the literature. 
  
                            REVIEW OF LITERATURE 
 The words of Brigden et al written in 1960, remain true today: “Heart 
lesions develop in nearly all SLE patients at some time during the course of 
their disease when life is prolonged by modern therapy.
7
 
HISTORY 
 The pathologic study of cardiac lupus dates from the report of Libman 
and sacks of verrucous endocarditis.
8
 
 The first recognition of cardiac involvement in lupus was a report by 
kaposi in 1872 of cardiac irregularity and dyspnea.
9 
                       CARDIAC MANIFESTATIONS OF SLE 
1. PERICARDITIS 
 Pericarditis tends to be one of the earlier cardiac manifestations and can 
even be the first manifestation of lupus.
10 
 Pericarditis is the most frequent cardiac manifestation.
1 
 Pericarditis usually appears as an isolated attack or as recurrent episodes, 
with or without symptoms.
7 
 
 In a French series, of 28 patients with pericarditis, 23 had pain, 12 had 
rub, and 4 required pericardiocentesis because of tamponade.
11 
 
          Patients with pericardial effusion are more likely to have pericardial pain 
and active lupus.
12
 Pericardial tamponade has been reported.
10
 constrictive 
pericarditis is very rare.
13 
PREVALENCE  
 Pericarditis occurs in 12 – 47% of living SLE patients24 
          Autopsy studies find a much higher prevalence of pericardial involvement  
ranging upto 61 – 100%.31  
                        PREVALENCE OF PERICARDITIS 
Study No of patients Clinical ascertainment (%) 
Armas – Cruz et al74 
Griffith & Vural
31 
Brigden et al
7 
Harvey et al
78 
Estes & christian
50 
Kong et al
20 
Badui et al
37 
Sturfelt et al
75 
Pistiner et al
65 
108 
18 
60 
138 
150 
30 
100 
75 
464 
12% 
17% 
43% 
45.7% 
19.3% 
47% 
25% 
35% 
12% 
 
 
PATHOLOGY 
 The histopathology in a case of pericarditis showed fibrosis, chronic 
inflammation with IgG, IgM and complement deposition on 
immunofluorescence.
13
 
 On immunofluorescence, IgG was present in a predominantly granular 
pattern around small pericardial vessels. Thus, Bidani and colleagues concluded 
that immune complex deposition was the cause of pericarditis.
14
 
 
 At autopsy, a diffuse or focal fibrinous pericarditis , often with many 
hematoxylin bodies, with or without effusion is found.
7 
 Pericardial fluid is usually exudative, varying in amount from 100 to 
more than 1000cc.
10
 WBC counts are in the 30,000 range, primarily neutrophils.  
                   PREVALENCE OF PERICARDIAL EFFUSION  
Study No of Patients 
Prevalence of effusion by 
Echocardiography 
Ito et al
70
 
Chia et al
76 
Crozier et al
80 
Doherty et al
77 
Sturfelt et al
75 
48 
21 
50 
50 
75 
46% 
24% 
54% 
42% 
19% 
                                
 
 Hunder et al found complement fixing immune complexes in the 
pericardial fluid of SLE patients.
69 
  Anti DNA antibodies and low complement levels are seen in pericardial 
fluid.
16
 
 
DIAGNOSIS 
 The diagnosis of pericarditis was based on the presence of a pericardial 
friction rub in 71%, ECG changes in 33% and on evidence of pericardial 
effusion in 50% of the patients.
24
 
 The diagnosis of pericarditis can be confirmed by ECG findings of 
elevated ST segments and tall T waves, or by cardiac echocardiogram findings 
of pericardial effusion or thickened pericardium.
67
 
 Serial ECGs may show a progression of changes in pericarditis. Initially  
a diffuse elevation of ST segments. This is followed by a lowering of ST 
segments back toward baseline and subsequent T wave inversion. In most cases,  
T waves then return to normal.
17 
TREATMENT 
 NSAIDS are the mainstay therapy
1.
 Patients with pericardial tamponade 
may necessitate pericardiocentesis.
67 
2.MYOCARDITIS  
  Most myocarditis in SLE is subclinical.  The clinical detection of 
myocarditis ranges from 3% to 15%.
67
 
PREVALENCE OF MYOCARDITIS 
Study No of patients Clinical Diagnosis(%) 
Estes & Christian
50 
Borenstein et al
96 
Dubois  & tuffanelli
97 
Ropes
98 
Badui et al
37
  
Godeau et al 
11 
150 
140 
520 
128 
100 
103 
8% 
3.6% 
8% 
10% 
14% 
14.5% 
 
 Myocarditis should be considered in patients with tachycardia not due to 
fever, in patients with a third heart sound (S3), in patients with abnormal ECGs, 
in those with new murmurs or conduction disturbances, and in those with 
congestive cardiac failure.
10
 
 
 
 
PATHOLOGY 
 Myocarditis in SLE is a complicated process, with arteritis or 
arteriopathy, not primary disease of the myocardial fibers.
18 
  Immunofluorescence studies of endomyocardial biopsies reveal 
perivascular deposits of IgG and vascular deposits of C3.
19 
 Kong et al found pathologic evidence of myocarditis – fibrinoid and 
collagenous degeneration, interstitial edema, necrosis, and cellular infiltration in 
15 of 30 autopsies.
20
 
DIAGNOSIS 
 The diagnosis of myocarditis can be made out by elevated Troponin 
levels, ECG abnormalities and  supported by the finding of global hypokinesis 
on cardiac echocardiogram and confirmed by right ventricular endomyocardial 
biopsy.
21
 
   Hejtmancik et al made a clinical diagnosis of myocarditis in 21% of 
their patients based on  
 1.Cardiac enlargement 
 2.Conspicuous ventricular gallop rhythm 
 3.ECG abnormalities
24
. 
  
TREATMENT
 
 Treatment with high dose intravenous methylprednisolone, followed by 
high dose intravenous or oral corticosteroid maintenance therapy is indicated. 
 The addition of intravenous pulse cyclophosphamide , in refractory cases, may 
be helpful.
67
 
 Efficacy of therapy can be assessed by serial echocardiographic studies or 
right ventricular endomyocardial biopsies.
23
 
 
3. LEFT VENTRICULAR DYSFUNCTION 
 Echocardiographic studies consistently show that 4-71% of SLE patients 
have some degree of left ventricular dysfunction. 
12, 24 
PREVALENCE OF LEFT VENTRICULAR DYSFUNCTION 
          Study   No of patients          Frequency(%) 
Chia et al
76 
Roldan et al
35 
Leung et al
12
  
Doherty et al
77 
21 
54 
75 
50 
71% 
20% 
5% 
10% 
 
 SLE patients may have systolic dysfunction that only becomes apparent 
with exercise.
25
 Diastolic dysfunction although subclinical is found more 
consistently.
26, 27 
 Giunta et al found that disease duration was longer in patients with 
diastolic dysfunction.
27
similarly Enomoto et al found that diastolic function 
deteriorated progressively with age.
26
 
PATHOLOGY 
 The study of Strauer et al found multiple abnormalities in SLE patients 
including, 
  1. Increased end diastolic pressures. 
  2. Decreased contractility. 
  3. Decreased left ventricular ejection fraction. 
  4. Increased left ventricular stiffness. 
  5. Reduction of coronary vascular reserve.
28
 
       Corticosteroid therapy could contribute to ventricular dysfunction 
through multiple mechanisms, including fatty infiltration.
54
 A second potential 
factor is hypertension aggravated by corticosteroids.
86
 
 
DIAGNOSIS 
 The diagnosis of subtle degrees of left ventricular systolic or diastolic 
dysfunction is made echocardiographically.
67
 
 Left ventricular systolic function can be evaluated by the left ventricular 
ejection fraction
67
. 
 Diastolic function can be determined by the diastolic descent rate of the 
anterior mitral leaflet, The ratio of mean systolic velocity to mean diastolic 
velocity to mean diastolic velocity in the left ventricular posterior wall.
26
 
TREATMENT 
 Ventricular dysfunction that progressively worsens in inactive patients 
might be best addressed by aggressive risk factor modification and 
pharmacologic therapy.
71
 However   ventricular function worsening with active 
lupus might improve with corticosteroid treatment.
70 
 
4.VALVULAR DISEASE 
  The prevalence of valvular disease in SLE is very high.
12, 24, 29
 
                     
 
 
PREVALENCE OF VALVULAR DISEASE 
Study No of patients Valvular disease Frequency(%) 
Leung et al
12 
 
 
 
Sturfelt et al
75 
 
 
 
Guinta et al
27 
 
Galve et al
84 
 
Badui et al
37 
75 
 
 
 
75 
 
 
 
75 
 
74 
 
100 
Valve thickening-gross 
Valve thickening-focal 
Mitral regurgitation 
Aortic regurgitation 
Valve thickening 
Mitral regurgitation 
Aortic regurgitation  
Vegetations  
Valve thickening  
Vegetations 
Mitral valve thickening  
 
Vegetations 
 
 Valvular disease 
8% 
12% 
25% 
8% 
45% 
39% 
13% 
4% 
12% 
4% 
12% 
9% 
9% 
 
 
 
 
 
PATHOLOGY
 
 The mitral valve is affected most often, followed by the aortic valve. 
Mitral and aortic regurgitation are the most common findings, with stenotic 
lesions being very rare.
67
 
 The typical valvular and mural endocarditis lesions, which are verrucous, 
occur as a single vegetation or as mulberry like clusters. When occuring on 
valves the vegetations are often on the ventricular surface, near, but not 
distorting, the line of closure.
30
 
 In the corticosteroid era, valvular vegetations are found less frequently.
67
 
Shearn found that none of the 11 patients who received corticosteroids had 
verrucous endocarditis.
10 
 The original histologic description of Libman-Sacks endocarditis 
emphasized the multiplication of endothelial cells, proliferation of Anitschow 
myocytes, and infiltration of mononuclear cells in the valve ring and valve base, 
especially the valve pocket.
32, 33
 
 Immunofluorescence showed immunoglobulin and complement 
deposition in the walls of small junctional vessels in the inner zone of 
neovascularization, suggesting that circulating immune complexes were critical 
in the development of the vegetations.
30
 
 Galve et al found that patients with Libman-sacks endocarditis were 
younger, had shorter disease duration, and had received less corticosteroid 
therapy than those with thickened valves.
84
  
 
CLINICAL FEATURES 
    Shearn found that systolic murmurs occurred in 70% of SLE patients. 
Diastolic murmurs occur in only 4% of SLE patients.
74, 
 Griffith and vural heard murmurs in only two of six patients with 
Libman-Sacks endocarditis, and vice versa, found Libman-Sacks endocarditis in 
only two of seven patients with systolic murmurs.
31
 
DIAGNOSIS 
 Transesophageal echocardiogram is the modality of choice in terms of  
sensitivity in detecting valvular disease due to lupus.
34, 35 
TREATMENT 
 SLE patients with large , sterile vegetations should be anticoagulated to 
lessen embolic complications. High dose corticosteroids for 4 to 6 weeks to 
shrink vegetations is controversial.
36
  
 
5.ARRYTHMIAS AND  CONDUCTION DISTURBANCES 
 The strongest association of SLE with conduction disturbance is 
congenital heart block, usually in the setting of maternal anti-RO and anti-
La.
38,39
 
 
PREVALENCE 
 Approximately 10% of adult SLE patients have conduction 
disturbances.
11, 37
 
 Sinus tachycardia is found in 6 – 100% of patients24, 
  Arrhythmias are found more commonly in SLE patients with pericarditis 
and myocarditis.
67
 
                                
                         PREVALENCE OF SINUS TACHYCARDIA 
Study Frequency (%) 
Badui et al
37 
Griffith & Vural
31 
Hejtmancik et al
24 
11 % 
100% 
50% 
 
 
PATHOLOGY 
 Autopsy studies of SLE patients have found arteritis of the sinus node, 
vascular occlusion, vasculopathy, and fibroblastic replacement of the sinoatrial 
and atrioventricular nodes.
40 
 
DIAGNOSIS 
 Accurate ascertainment of arrhythmias requires continuous ECG 
monitoring.
67
 
TREATMENT 
 SLE patients with life-threatening conduction defects can be treated with 
permanent pacemakers.
41
 
 
6.CORONARY ARTERITIS. 
Coronary arteritis is extremely rare in SLE. In some cases, it has been found at 
autopsy, with no clinical correlate during life.
67
 
 
 
 
 
PREVALENCE 
 There are few studies that allow any estimate of the prevalence of 
coronary arteritis.
7, 24, 18, 20
. 
 In one study in 1960, 6 of the 16 patients were found to have arteritis at 
biopsy.
24 
                                      CORONARY ARTERITIS 
Case report or series       No of patients    Age at diagnosis 
Homcy et al
44 
Bonfiglio
42 
Korbet et al
43 
Heibel et al
45 
Hejtmancik et al
24 
Brigden et al
7 
Kong et al
20 
Simon et al
18 
3 
1 
1 
1 
6 
2 
1 
1 
27, 34, 21 
16 
26 
45 
- 
- 
- 
25 
 
 
CLINICAL FEATURES 
 The most common clinical presentation is angina, myocardial infarction, 
or both in a child or young adult.
67
 
PATHOLOGY 
 Histopathology demonstrates transmural vasculitis.
42 
Immunofluorescence studies demonstrate immunoglobulin and complement 
deposition in coronary arteritis.
43 
 
DIAGNOSIS 
 It is often difficult to distinguish coronary arteritis from accelerated 
atherosclerosis. Serial coronary angiography has been proposed as the most 
useful diagnostic modality.
44, 45
 Arteritis is suggested when coronary aneurysms 
are found, if there are smooth focal lesions, or if there are rapidly developing 
stenoses.
44, 45 
TREATMENT 
 The differentiation of coronary arteritis from atherosclerosis is essential 
for appropriate management. Coronary artery bypass surgery, angioplasty, or 
stent placement would be contraindicated in patients with coronary arteritis.
67
 
 Case reports suggest that corticosteroid therapy can have rapid benefit in 
patients with coronary arteritis.
67
 
 
 
7. PULMONARY HYPERTENSION 
 Pulmonary hypertension is unusual in SLE patients. Earlier studies, 
which determined the prevalence clinically, found a cumulative frequency of 
only 2-9%.
67
 
             
PREVALENCE OF PULMONARY HYPERTENSION 
           Study       No of patients      Frequency(%) 
Brigden et al
7 
Perez & Kramer
46
  
Badui et al 
37 
Crozier et al
80 
Hejtmancik et al
24 
Quismorio et al
82 
Simonson et al
83 
Leung et al
12 
60 
43 
100 
50 
142 
400 
36 
75 
3% 
9% 
9% 
2% 
1% 
1% 
14% 
1% 
 
CLINICAL FEATURES 
  It is usually asymptomatic, discovered on a screening ECHO Doppler.  
 Rare SLE patients will present with chest pain, dyspnea, or even pedal 
edema and be found to have pulmonary hypertension.
67 
 
PATHOLOGY 
 Several lines of evidence suggest that pulmonary hypertension may be a 
complication of pulmonary artery vasospasm.
67 
 Raynaud’s phenomenon is more common in SLE patients with 
pulmonary hypertension.
46, 47 
 In one series of SLE patients, those with pulmonary hypertension by 
Doppler had a shorter duration of SLE and corticosteroid therapy and a higher 
prevalence of Raynaud’s phenomenon.82 
 
DIAGNOSIS 
 Diagnosis is best made by Doppler echocardiography. Doppler 
echocardiography has a close correlation with simultaneous right heart 
catheterization measurement of pulmonary artery pressures. Owing to invasive 
nature right heart catheterization is more appropriately reserved for 
symptomatic patients.
67
 
 
 
TREATMENT 
 Treatment is now available for severe pulmonary hypertension with the 
advent of continuous intravenous prostracyclin and its analogs.
48
 Patients with 
severe pulmonary hypertension should be anticoagulated.
49 
8. HYPERTENSION 
 Although earlier studies did not find a high prevalence of hypertension in 
SLE patients because of shortened survival, more recent studies have found a 
high frequency of up to 50%.
67
 
 Several studies found that hypertension was more common in those with 
underlying lupus nephropathy.
10 
PREVALENCE OF HYPERTENSION 
                   Study                   Prevalence(%)  
Harvey et al
78 
Shearn
10 
Brigden et al
7 
Kong et al
20
  
Hejmancik et al
24 
Okado & Shiokawa
85 
Budman & Steinberg
79 
Doherty et al
77 
Crozier et al
80 
Schioppati & Remuzzi
81 
14% 
32% 
44% 
53% 
22% 
44% 
45% 
50% 
14% 
                        40% 
 86% of SLE patients with hypertension had lupus nephritis in the series 
of Estes and Christian.
50 
 Pollack and Kant found a correlation of mean diastolic blood pressure 
and increasing renal damage.
51 
 Hypertension is likely to develop or worsen when patients with lupus 
nephropathy are given corticosteroids.
52
 
  When examined the relationship of prednisone and blood pressure using 
the Hopkins Lupus cohort database, it is found that an increase in Prednisone 
dose of 10mg led to an increase in mean arterial pressure, adjusting for all other 
factors that affect blood pressure.
66
  
TREATMENT 
 As many hypertensive patients with SLE have underlying renal disease, 
long term benefit of ACE inhibitors is lessening of renal scarring.
53 
 ACE inhibitors are well tolerated in SLE, although an occasional patient 
may develop an ACE inhibitor induced chronic cough.
67
 
 
 9. CORONARY ATHEROSCLEROSIS IN SLE. 
 coronary atherosclerosis is a clinical conundrum of the modern era of 
lupus management
67
. 
  Myocardial infarction was not common in early autopsy series, but was a 
major feature of the Bulkley and Roberts and subsequent autopsy series.
54 
 Patients usually present in early 40s with angina, myocardial infarction or 
sudden death. However, patients have presented in their early 20s with coronary 
atherosclerosis.
55
 
 Clinically, the patient may present with anginal pain, stable or unstable 
angina, acute myocardial infarction or heart failure. The differential diagnosis 
includes coronary arteritis, thrombosis secondary to antiphospholipid antibody 
syndrome or coronary vasospasm.
67
 
 
 
 
PATHOGENESIS 
 IMMUNE COMPLEX OR ARTERITIS 
  Although coronary arteritis  is rarely detected ante mortem autopsy 
studies have detected it frequently.
31, 54
 
 Immune complexes from lupus sera accelerated uptake of cholesterol by 
smooth muscle cells.
56
 vascular injury, through immune complexes, followed by 
exposure to atherosclerotic risk factors, can lead to atherosclerosis.
57 
 
 Both arteritis and atherosclerosis have been found within a single patient, 
suggesting that arteritis might have predisposed to the later development of 
atherosclerosis.
24
 
 SLE Patients treated with corticosteroids had less intimal proliferation in 
their coronary vessels, suggesting that suppression of arteritis might lead to less 
atherosclerosis.
58 
ANTI-PHOSPHOLIPID ANTIBODIES 
 Anti-phospholipid antibodies contribute to coronary artery disease 
through thrombosis
59
 or vasculopathy.
60 
 Anti-phospholipid antibodies function as antibodies against oxidized 
lipoproteins, by which they contribute to atherosclerosis.
61 
 Beta 2 glycoprotein 1, an important control against atherosclerosis is 
perturbed by anti-phospholipid antibodies.
62 
 
PREVALENCE OF CORONARY ARTERY DISEASE 
Prospective studies have found, using the clinical detection of angina, 
myocardial infarction, or both, frequencies on the order of 7-9%.
11, 12
 
 
 
Study No of patients Modality Frequency(%) 
Kong et al
20 
 
Bulkley& 
Roberts
54 
 
Sturfelt et al
75 
 
 
Hetjmancik
24 
 
 
Badui et al
37 
 
Urowitz et al
100 
 
Griffith & Vural
31
  
 
Bidani et al
14 
 
30 
 
36 
 
 
75 
 
 
142 
 
 
100 
 
81 
 
11 
 
10 
Myocardial infarction 
  
 >50% narrowing 
Myocardial infarction 
 
Myocardial infarction 
Exercise induced 
Ischemia 
Angina in 6 patients, 
EKG changes in 4 
          
                - 
 
Angina, 
Myocardial infarction 
          - 
 
          - 
7% 
 
22% 
11% 
 
9% 
11% 
 
4.9% 
 
 
16% 
 
7.4% 
 
45% 
 
10% 
 
RISK FACTORS FOR CAHD IN SLE 
  Some of the risk factor could be due to SLE . Hypertension, for example 
is more prevalent in SLE patients with renal disease.
74, 50
 
  Prolonged corticosteroid therapy could precipitate atherosclerosis 
indirectly by hypertension, hypercholesterolemia, hypertriglyceridemia, 
diabetes mellitus, obesity and hyperhomocysteinemia or directly, via vascular 
injury
87
. 
  HYPERTENSION 
          Hypertension is very  prevalent in SLE patients and is aggravated by 
corticosteroids.
66
 
HYPERLIPIDEMIA 
  Hyperlipidemia in SLE has two major patterns  
FIRST PATTERN 
 Low HDL 
 Low apoprotein A1 
 Elevated VLDL 
 Elevated triglycerides   
 This pattern is seen in active disease.
88 
SECOND PATTERN 
 High triglycerides 
 High LDL 
 High total cholesterol 
 This pattern occurs in SLE patients on corticosteroids.
89 
 
HYPERHOMOCYSTEINEMIA 
  Homocysteine is an amino acid that has a direct toxic effect on 
endothelium
90
 and indirect effects, including promotion of vascular smooth 
muscle proliferation and an inhibitory effect on endothelial cell growth
91
.  
  In the Hopkins Lupus cohort study, 15% of the 337 SLE patients had 
elevated homocysteine.
67 
  Raised homocysteine levels are associated with CAHD, stroke and 
arterial thrombosis.
92 
 
 
 
 
PREVALENCE OF CAHD RISK FACTORS
67 
                   Risk factor              Prevalence (%) 
Family history  
Hypertension 
Hypercholesterolemia 
Obesity 
Smoking 
Sedentary lifestyle 
Diabetes 
Homocysteine 
41% 
48% 
56% 
38% 
56% 
70% 
7% 
15% 
 
DIAGNOSIS 
 Coronary Angiography remains the gold standard for the diagnosis of 
coronary artery disease.
67
  
Rest and perfusion myocardial single emission Computed Tomography 
(SPECT) scans are currently one of the most sensitive and specific means of 
assessing the presence of atherosclerosis.
93
 
TREATMENT 
 The acute management of  an SLE patient with myocardial infarction is 
similar to that of a non SLE patient.
67
 
 High dose corticosteroid therapy should only be given at the time of 
myocardial infarction if there is proof of arteritis by angiogram or a very high 
suspicion based on extra cardiac active lupus, because of the possible adverse 
effect it may have in causing marked scar thinning
94
. 
FUTURE TREATMENT 
 The presence of macrophages and activated T cells in atherosclerotic 
plaques suggest that immunity plays a role in atherosclerotic progression. CD40 
– CD40 ligand interactions may be important in the development of 
atherosclerosis
67
. 
 In atherosclerotic plaques, triggering of CD40L on T cells leads to 
regulation of T-cell expansion and cytokine production
95
.  
 Anti – CD40 ligand, therapy already being considered as a novel way to 
treat SLE may have the additional benefit of retarding atherosclerosis
67
. 
CARDIOVASCULAR MORTALITTY 
 Urowitz and colleagues drew attention to the bimodal pattern of mortality 
in SLE, with early deaths due to active disease and infection and later deaths 
due to cardiovascular disease.
63 
             
         
                                  CARDIOVASCULAR MORTALITY 
Study Death due to cardiovascular disease (%) 
Urowitz et al
100 
Karsh et al
73 
Wallace et al
64 
Rosner et al
87 
Pistiner et al
65 
45% 
25% 
20% 
3% 
15% 
 
 
 In the study of causes of death in 144 SLE patients, cardiovascular 
disease was the third leading cause of death
67
. 
  With better survival of SLE patients, both the morbidity and mortality 
from accelerated atherosclerosis tend to increase.
50, 65, 66 
 
 
  
 
 
 
  
                         MATERIALS AND METHODS 
 
 The study was conducted in Thanjavur Medical College Hospital, 
Thanjavur, Tamilnadu. The study was conducted in the Department                           
of Internal Medicine. The study period extended between June 2009 and 
October 2010. It was a carefully selected study population of SLE                  
based on 1997 UPDATE OF THE 1982 AMERICAN COLLEGE OF 
RHEUMATOLOGY CLASSIFICATION CRITERIA FOR SLE. 
 The patients were selected on the basis of inclusion and exclusion criteria 
and cardiac evaluation was done. 
INCLUSION CRITERIA 
  All registered cases of SLE ( diagnosed on the basis of 1997 UPDATE 
OF THE 1982 AMERICAN COLLEGE OF RHEUMATOLOGY 
CLASSIFICATION CRITERIA FOR SLE)  attending Nephrology, Cardiology 
and Medical departments are included for the study 
EXCLUSION CRITERIA 
Tuberculosis  
Rheumatic heart disease 
Uremia 
Intake of drugs or conditions other than SLE, producing positive ANA. 
  A profoma was drafted including the details about the presenting illness 
and all patients were subjected to routine physical examination including 
detailed  cardiovascular examination. 
 Routine blood investigations like complete hemogram, blood sugar, blood 
urea, serum creatinine, serum electrolytes and erythrocyte sedimentation rate 
were done. 
 Complete urine analysis including urine albumin, deposits and 24 hours 
urinary protein  were done. 
 ANA and dsDNA tests were done for all patients. Anti phospholipid 
antibody test was done for patients who gave history of fetal wastage. 
 After taking ECG and X ray chest, all patients were subjected to 
Echocardiography. 
 
  
 
 
 
                            
 
Patient Name : Miss. Gomathi 
Age: 22 Years 
IP Number: 1088786 
 
A SYSTEMIC LUPUS 
ERYTHEMATOSUS PATIENT 
WITH MALAR RASH AND ALOPECIA 
AGE DISTRIBUTION 
AGE NO OF PATIENTS PERCENTAGE 
< 15 1 2% 
15 - 20 7 14% 
21 - 25 8 16% 
26 - 30 8 16% 
31 - 35 11 22% 
36 - 40 8 16% 
41 - 45 3 6% 
46 - 50 3 6% 
>50 1 2% 
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SEX DISTRIBUTION
MALE
FEMALE
SEX NO OF PATIENTS PERCENTAGE 
       MALE 5 10% 
      FEMALE 45 90% 
                DISTRIBUTION OF CLINICAL SYMPTOMS 
 
SYMPTOMS NO  OF PATIENTS PERCENTAGE 
CHEST PAIN 
   PERICARDITIC 
   ANGINAL 
   NON CARDIAC 
37 
7 
11 
19 
74% 
14% 
22% 
38% 
DYSPNEA 14 28% 
PALPITATIONS 9 18% 
SYNCOPE 3 6% 
RAYNAUD’S 
PHENOMENON 
15 30% 
PHOTO SENSITIVITY 24 48% 
SEIZURES 3 6% 
FETAL WASTAGE 7 14% 
ORAL ULCERS 13 26% 
ALOPECIA/ HAIR LOSS 16 32% 
 
  
0
5
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DISTRIBUTION OF SIGNS 
          
 
 
SIGNS NO OF PATIENTS PERCENTAGE 
MALAR/DISCOID 
RASH 
23 46% 
ARTHRITIS 6 12% 
HYPERTENSION 29 58% 
ELEVATED JVP 5 10% 
PERICARDIAL RUB 7 14% 
S3 4 8% 
BASAL CRACKLES 4 8% 
LOUD A2 10 20% 
LOUD P2 3 6% 
MURMURS 
       SYSTOLIC 
      DIASTOLIC 
 
13 
4 
 
26% 
8% 
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92
8
PERCENTAGE OF ANA POSITIVITY
ANA POSITIVE
ANA NEGATIVE
ANTI  NUCLEAR 
ANTIBODY 
NO OF PATIENTS PERCENTAGE 
POSITIVE 46 92% 
NEGATIVE 4 8% 
DISTRIBUTION OF ECG CHANGES 
 
ECG CHANGES 
NO OF 
PATIENTS 
PERCENTAGE 
SINUS  TACHYCARDIA 23 46% 
T INVERSION 17 34% 
ST DEPRESSION 4 8% 
PR DEPRESSION 3 6% 
LVH STRAIN 11 22% 
 LOW VOLTAGE 
COMPLEXES 
3 6% 
RIGHT BUNDLE 
BRANCH BLOCK 
3 6% 
LEFT ANTERIOR 
HEMIBLOCK 
2 4% 
FIRST DEGREE 
AVBLOCK 
1 2% 
NORMAL 16 32% 
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DISTRIBUTION OF ECG CHANGES
NO OF PATIENTS
  
PATIENT  NAME : PRIYA       AGE: 27 YEARS       IP NUMBER : 1065273 
ECG SHOWING T WAVE INVENSION INFROLATERAL LEADS WITH LVH STRAIN PATTERN 
   
PATIENT  NAME : THANGAM       AGE: 50 YEARS       IP NUMBER : 1059231 
ECG SHOWING SINUS TACHYTARDIA WITH LOW VOLTAGE COMPLEXES 
DISTRIBUTION OF ECHOCARDIOGRAPHIC   CHANGES 
ECHO FINDINGS 
NO OF 
PATIENTS 
PERCENTAGE 
PERICARDIAL EFFUSION 20 40% 
MVPS 14 28% 
MITRAL REGURGITATION 13 26% 
MVPS WITH MITRAL 
REGURGITATION 
10 20% 
MVPS WITH OUT MITRAL 
REGURGITATION 
4 8% 
AORTIC REGURGITATION 4 8% 
TRICUSPID REGURGITATION 3 6% 
PULMONARY HYPERTENSION 3 6% 
LIBMAN – SACKS 
ENDOCARDITIS 
1 2% 
SYSTOLIC DYSFUNCTION 4 8% 
DIASTOLIC DYSFUNCTION 6 12% 
HYPOKINESIS 
         GLOBAL 
         REGIONAL 
10 
4 
6 
20% 
8% 
12% 
NORMAL 20 40% 
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 RESULTS AND OBSERVATIONS 
 
 The study population included 50 Systemic Lupus Erythematosus 
patients, of whom 45 patients are females and 5 are males, with majority of 
patients distributed between the age group of 20 to 40 years. The lowest age is 
13 years and the highest age is 60 years. The maximum prevalence of SLE is in 
the age group of 31 to 35 years. 
  Out of 50 Systemic Lupus Erythematosus patients 46 patients are positive 
for Anti Nuclear Antibody and 4 patients are negative for Anti Nuclear 
Antibody. 
  37 out of 50 patients had chest pain, of whom11 patients had anginal type 
of pain, 7 had pericarditis type of pain, and 19 had non specific chest pain. 
 Among 50 patients, 14 patients had dyspnea, 9 patients had palpitations 
and 3 patients had syncope 
 Cutaneous photosensitivity was noted in 24 patients, 23 patients had 
Malar / Discoid rash, 15 patients had positive Raynaud’s phenomenon. 
 Out of 50 patients 7 female patients had previous fetal wastage, all are 
positive for Antiphospholipid antibodies and 3 patients had history of seizures. 
 13 patients had oral ulcers, 16 patients had alopecia / hair loss, 6 patients 
had Arthritis and 44 patients had Lupus nephropathy.  
  Systemic hypertension was found in 29 patients and all patients had 
associated Lupus nephropathy 
 Of the 50 SLE patients, 5 patients  had elevated JVP , 7 patients had 
pericardial rub, Loud aortic component of second heart sound was found in 10 
patients, loud pulmonary component of second heart sound was found in 3 
patients, 4 patients had third heart sound  on auscultation. Systolic murmurs 
were found in 13 patients and 4 patients had diastolic murmurs. 
 Bilateral basal crackles was found in 4 patients due to left ventricular 
dysfunction, in these patients the x ray chest taken ruled out the possibility of 
respiratory disease to prove basal crackles are due to cardiac disease. 
ECG CHANGES 
  Normal ECG was found in 16 SLE patients, 23 patients had sinus 
tachycardia. T wave inversion was found in 17 patients , 11 patients had  LVH 
strain, 4 patients showed ST depression and 3 patients showed PR depression in 
their ECG. Low voltage complexes  was found in 3 patients, 6 patients had 
conduction disturbances in their ECG, out of which 3 patients had Right Bundle 
Branch  Block, 2 patients had Left Anterior Hemi Block  and 1 patient had first 
degree AV block. 
 
 X RAY  
 Out of 50 SLE patients 9 patients showed cardiomegaly ( Cardio 
Thoracic ratio > 0.5 ) in their X – rays.  
  ECHOCARDIOGRAPHIC FINDINGS 
 Among 50 patients 20 patients had normal Echocardiography  
 20 out of 50 patients had pericardial effusion, which is the commonest 
echocardiographic finding. Of these 20 patients ,15 had mild pericardial 
effusion and 5 had moderate  pericardial effusion , massive pericardial effusion 
so as to cause cardiac tamponade was found in no patient. 
 14 patients had mitral valve prolapse, 13 patients had mitral regurgitation 
and 10 patients had MVPS associated with mitral regurgitation . 
 Out of 50 patients 4 patients had Aortic regurgitation , 3 patients had 
tricuspid regurgitation , pulmonary hypertension was found in 3 patients and 1 
patient had Libman-sacks endocarditis 
 10 patients had left ventricular dysfunction of whom 4 patients had 
systolic dysfunction and 6 patients had diastolic dysfunction. 
 Out of 50 SLE patients 4 patients had global hypokinesia and 6 patients 
had regional hypokinesia in their ECHO 
 
                                        DISCUSSION 
 
PERICARDITIS 
 In this study  Pericarditis is the most common cardiac manifestation. 
 Armas – Cruz et al ,Brigden et al and Kong et al showed that pericarditis 
is the most common cardiac manifestation in SLE patients ranging from 12 – 
47% 
7,20,74
, prevalence of pericarditis in our study is 40% which tally with the 
literature finding. 
 
 
 MITRAL REGURGITATION 
 Valvular heart disease is the second most common cardiac manifestation 
in SLE next to pericarditis 
  Leung et al and Sturfelt et al showed that 25 – 39% of SLE cases had 
mitral regurgitation.
12, 75
 Here, in our study, 13 out of 50 SLE patients had mitral 
regurgitation accounting  for 26% . This finding also coincides with the literature 
quoted.  
 
  
 
AORTIC REGURGITATION 
  Leung et al and Sturfelt et al showed that Aortic regurgitation occurs in 8 
– 13% of SLE patients.12, 75 
  In this study Aortic regurjutation is observed in 4 patients accounting for 
8%. This finding also tally with the literature. 
 
 
LIBMAN – SACKS ENDOCARDITIS 
  According to studies conducted by Sturfelt et al, Giunta et al and Galve et 
al Libman – Sacks endocarditis occurs in 4 – 9% of SLE patients.75,84 Libman-
Sacks lesions have been noted in 25% to 100% and infective endocarditis in 1.1 
to 4.9% of clinical and autopsy studies done by Doherty NE.
101
 In our study 
endocarditis  is observed echocardiographically in 1 patient accounting for 2% , 
the prevalence of endocarditis is lesser when compared to the literature. The 
lower prevalence could be due to the use of steroids , as majority of the patients 
are receiving treatment for associated Lupus nephropathy(88%). 
  
 
 ARRHYTHMIAS AND CONDUCTION DISTURBANCES 
  According to Badui et al and Griffith and Vural et al sinus tachycardia 
occurs in 11 to 100%.
31, 37
 In our study sinus tachycardia occurred in 23 patients 
accounting for 46%. Approximately 10% of SLE patients have conduction 
disturbances.
11, 32, 85
 In this study 6 patients had conduction disturbances 
accounting for 12%. Of whom 3 patients had Right Bundle Branch Block, 2 
patients had Left Anterior Hemi Block and 1 patient had first degree AV block. 
 
 
HYPERTENSION 
  Harvey et al, Kong et al, Budman and Steinberg et al, Doherty et al , 
Crozier et al, Shieppati and Remuzzi et al showed that hypertension is  seen in 
SLE patients of about 14 – 53 %20, 77, 78, 79, 80, 81 
  In this study hypertension is observed in 29 patients which is about 58 %. 
This higher prevalence of hypertension is due to associated lupus 
nephropathy(88%) and the patients are receiving steroids for it. 
  
 
PULMONARY HYPERTENSION 
  Hejtmancik et al, Perez and Kramer  et al, Quismorio et al, Surfeit et al 
and Simonson et al showed that pulmonary hypertension occurs in 1 – 9% of 
patients with SLE.
24, 45, 75, 82, 83
 In this study pulmonary hypertension is found in 3 
patients accounting for 6%. This finding also tally with  the literature quoted. 
 
 
LEFT VENTRICULAR DYSFUNCTION 
    Leung et al, Doherty et and Chia et al showed in their studies that left 
ventricular dysfunction occurs in about 4 – 71% of SLE patients.12,76,77  
  In this study, left ventricular dysfunction occurred in 10 patients , of 
whom 4 patients had systolic dysfunction  and 6 patients had diastolic 
dysfunction.  Overall 20% of the patients had left ventricular dysfunction,  this 
finding  also tally with the literature cited. 
 
 
  
 
GLOBAL OR REGIONAL HYPOKINESIA 
  Doherty et al, Sturfelt et al showed that Global hypokinesia of 
myocardium as evidenced by echocardiography occurs in 8 - 12% of  patients 
and regional hypokinesia in 7 – 16 % of the patients75, 77 
  In this study Global hypokinesia was seen in 4 patients accounting for 8%  
and Regional hypokinesia was seen in 6 patints accounting for 12%. this finding 
also coincides with the literature. 
 
 
 
 
 
 
 
 
                                  CONCLUSION 
 In our  study 72% of the  patients had cardiac manifestations. 
 The commonest cardiac manifestation is Pericarditis/ Pericardial effusion 
(40%). 
  Valvular disease is the second most common cardiac manifestation next 
to Pericarditis, ( 34%) with Mitral regurgitation/Mitral valve prolapse being the 
most common valvular disease, next common being Aortic regurgitation and the 
least common valvular abnormality is Tricuspid regurgitation. 
 In this study Systemic hypertension is found in 58% of the patients and 
pulmonary hypertension in 6% of the patients. 
 Left ventricular dysfunction is found in 20% of the patients, with systolic 
dysfunction being 8% and the diastolic dysfunction being 12%. 
 The commonest Arrhythmia found in this study is Sinus Tachycardia 
(46%) and the conduction disturbances noted are Right Bundle Branch 
Block(6%), Left Anterior Hemi Block(4%) and AV block (2%). 
 The least common cardiac finding is Libman – Sacks endocarditis, which 
is found in one case only (2%). 
           Almost all the cardiac findings are in par with what is seen in literature 
except for higher prevalence of systemic hypertension and lower prevalence of 
Libman – Sacks endocarditis. 
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                                                                 PROFORMA 
A STUDY ON CARDIOVASCULAR MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS                                
ERYTHEMATOSUS. 
Name                                                                                           Age                                Sex 
 
IP/OP number                                                                          Address                        
  HISTORY: 
       SYMPTOMS 
                 Chest pain 
                 Dyspnea 
                 Palpitations  
                 Photosensitivity 
                 Oral ulcers 
                 Hematuria 
                 Seizures 
                 Hallucinations 
                 Abnormal behaviour 
                 Fetal wastage  
                 Raynaud’s phenomenon 
   ON EXAMINATION: 
        SIGNS 
                 Pericardial rub 
                 Pleural rub 
                 Oral ulcers 
                 Arthritis 
                 Malar rash / Discoid rash 
               Petechiae 
              Purpura 
              Lymphadenopathy 
              Elevated  JVP 
Pulse rate: 
Blood pressure:  
Cardio vascular system: 
Respiratory system: 
Abdomen:  
Central nervous system:  
INVESTIGATIONS: 
         Urine albumin 
         Urine sugar 
         Urine deposits 
         24 hours urinary protein 
         Renal biopsy 
         Complete blood count 
         ESR 
         Antinuclear antibody  
         ds DNA 
         Antiphospholipid antibody  
         X ray chest PA view 
         ECG 
        ECHO 
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1 Kali ammal 50 F 049807  +   +   +  +  +    88 130/ 
      80 
1000 + 80           + + + +      
2 parameshwari 22 F 80609 +     +          72 160/ 
      90 
790 _ 60   +              +   
3 Kalai arasi 27 F 1044755  +   +   +        86 110/ 
      70 
820 + 80                    
4 Muthu 33 M 1100827 + +    +   +     +  112 116/ 
      70 
650 + 68 +   +     +           
5 Saravana 38 F 1042001   +     +        84 130/ 
      80 
780 + 54         +  +         
6 
 
vimala 48 F 141707 + +   + + + +   +     103 160/ 
     100 
960 + 50   + + +               
7 
 
Geetha 33 F 158409 +     +    +    + + 109 120/ 
       60 
1030 + 86 +        + + +         
8 
 
priya 27 F 1062573 +    + +          61 160/ 
       90 
980 + 34   +  +            +   
9 
 
usha 25 F 1064079 +     +     +     110 150/ 
     100 
590 + 50    +     + +          
10 
 
Amsavalli 35 F 1064738 +       +   +     70 160/ 
     100 
820 + 38                    
11 
 
Karthick 13 M 1091477 + +  +  +  +     +  + 138 90/ 
      60 
945 + 84 +   + +    +       +   + 
12 
 
Saranya 17 F 1063104      +          80 140/ 
     90 
860 + 56                    
13 
 
Thangam 50 F 1059231 +  +  +           123 110/ 
      70 
1250 + 76    +  +   +           
14 
 
Sathya 21 F 1063085  +      +   +     106 150/ 
      90 
710 + 39    +      +          
15 Angar begam 32 F 1056749  +   +   +  +   +   118 106/ 
       70 
880 + 70    +     + + +    + +  +  
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16 Dhana lakshmi 35 F 1056386 +     +  +      +  110 120/      
70 
650 + 64    + +  + + + + +         
17 
 
udhayanandini 19 F 1653398 +    +    +       89 150/       
90 
580 + 56   +                 
18 
 
Rekha 27 F 1052778 +   +  +  +        82 146/      
90 
980 + 48   +  +            + +  
19 
 
Shanthi 40 F 1048897  + +  + +  +        105 154/    
90 
1700 + 120    + +    +  + +        
20 
 
Udhaya sheela 18 F 1053409  +     +    +     72 150/     
90 
720 + 50                    
21 
 
Lakshmi 27 F 1004588 +    + +          109 110/      
50 
1560 _ 80    + +   + + + + +       + 
22 
 
Sounder nayagi 40 F 1045324 +     +  +        94 110/      
70 
2100 + 70                    
23 
 
Jaya kodi 37 F 104800 +    +   +        105 160/     
100 
790 + 46   + +                
24 
 
Uma shankari 18 F 1037921 +     +          109 120/      
60 
950 + 64  +  +     + + +       +  
25 
 
Malliga 37 F 1042497 +    + +  +   +     105 160/   
100 
750 + 45   + + +               
26 
 
Fathima beevi 39 F 1033056  + +     +        117 150/      
90 
3100 + 82    +     + +        +  
27 
 
Ishwarya 26 F 1071829 +             +  107 150/     
94 
1990 + 76    + +    + +          
28 
 
Divya 29 F 1080673 +    +      +     68 174/    
110 
690 _ 50                    
29 
 
Gomathi 22 F 1088786   +   +  +        92 100/      
70 
2700 + 50     +  +             
30 
 
Sentamil selvi 36 F 1081527  +   +           102 120/      
70 
800 + 86  +  +   +  +           
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31 Sivasamy 60 M 1092577 + 
 
         +     96 150/ 
     100 
655 + 90                    
32 Vijaya kumarai 
 
30 F 1091788 +     +  + +       82 170/ 
      90 
975 + 36   +  +            +   
33 Amutha 
 
32 F 1091771 +     +  +      +  104 100/ 
      70 
2400 + 76    + +    + + +         
34 Sudha 
 
32 F 9857/10 +  +  + +          112 120/ 
     80 
711 + 60 +   +                
35 Jaya lakshmi 45 F 113106 +  +      +       89 160/ 
     100 
1200 + 80   +  +            +   
36 Kanaga 21 F 1072663      +          88 154/ 
      90 
615 + 58                    
37 Abinaya 16 F 129210 +               104 110/ 
      70 
4900 + 100    +     + + +       +  
38 Kanaga valli 32 F 126110 +      + +   +     113 144/ 
    100 
590 + 58    + +     + +         
39 Mumtaj 18 F 0028/10 + +  +  +  +  +  + +  + 106 150/ 
      64 
600 + 110   + +      + + + + +  +   + 
40 Jothi 38 F 1051412 +   +    +        73 148/ 
      94 
1700 + 68                    
41 Ravi chandran 33 M 1006238 +               82 160/ 
     100 
960 + 50                    
42 Panjavarnam 43 F 1061491 +     +          85 120/ 
     70 
850 + 29                    
43 Gandhimathi 25 F 1102511 + +        +  + + + + 110 130/ 
     90 
710 + 40  +  +     + + +  + +  +   + 
44 Latha 24 F 803/09  + +        +     80 150/ 
    100 
2010 + 44                    
45 
 
Sabapathy 35 M 1013235 +               109 100/ 
      80 
1030 + 60    + + +   +           
 Ray phenomen  - Raynaud's Phenomenon                          Pericar rub – Pericardial rub                             LVH – Left Ventricular Hypertrophy       PHT  -  pulmonary Hypertension 
                                      
Photo sens -  Photosensitivity                                              BP – Blood Pressure                                            Sinus Taccy – Sinus Taccycardia              Sys dysfun – systolic Dysfunction                                                                              
 
JVP – Jugular Venous Pulse                                               ANA – Anti Nuclear Antibody                           LVC – Low Voltage Complexes                 Dia dysfun – Diastolic Dysfuncyion 
 
Basal crac – Basal crackles                                                 ESR – Erythrocyte Sedimentation Rate            RBBB – Right Bundle Branch Block        Reg Hyp Kn – Regional Hypokinesia 
 
A2  - Aortic component of second heart sound                 ST    - ST Segment Depression                           LAHB – Left Anterior Hemi Block           Glob Hyp Kn – Global Hypokinesia 
 
P2  - Pulmonary component of second heart sound         PR    - PR Segment Depression                          MR – Mitral Regurgitation                        ECG –  Electrocardiogram 
 
S3 – Third Heart Sound                                                      T      - T Wave Inversion                                     AR – Aortic Regurgitation                         ECHO –  Echo 
 
Pericard Ef  -  Pericardial Effusion                                   MVPS – Mitral Valve Prolapse Syndrome        TR – Tricuspid Regurgitation                   IP/OP no – Inpatient /Outpatient 
number 
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46 Rani 32 F 1093733 +               94 146/ 
     100 
510 + 46                    
47 
 
Kannagi 28 F 1083764 +  +   +   +     +  92 160/ 
      90 
970 + 64     +    +           
48 
 
Menaka 24 F 1077432 +    +   +        78 130/ 
     80 
860 + 54      +   +         +  
49 
 
Bavya 17 F 1012654 +     +  +        88 144/ 
      90 
560 _ 46                    
50 
 
Susila 45 F 1289/10 +               88 150/ 
    100 
690 + 80   +  +            +   
  
